Acarix (Nasdaq First North: ACARIX, OTCQB: ACIXF) announced that its CADScor® System has received regulatory approval from the Emirates Drug Establishment and the UAE Ministry of Health and Prevention, enabling commercial availability across the United Arab Emirates through partner UniTech Solutions.
The approval marks Acarix's entry into the Gulf region and a platform for broader GCC expansion. The CADScor System is a point-of-care diagnostic aid that uses acoustics, computational analysis, and AI to assess coronary blood flow and help rule out significant coronary artery disease in under 10 minutes, with at least 96% negative predictive value. The technology is CE-marked, FDA De Novo cleared, backed by over 15 years of R&D, 45 patents, and usage in more than 60,000 patient assessments.